## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

: Depui et al.

Serial No

: TBA

Filed

: TBA

For

: ORAL PHARMACEUTICAL DOSAGE

FORMS COMPRISING A PROTON

PROTON PUMP INHIBITOR AND A NSAID

Examiner

Group Art Unit

: 1615

"Express Mail" Label No. ET537319873US

Date of Deposit JULY 14, 2003

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to: MAIL STOP PATENT APPLICATION;

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

BERNARD MAYS

(Type or print name of person mailing paper or fee)

Signature

Date of Signature

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and

1.98.

The referenced application is a continuation of U.S. Patent Application Serial No. 10/090,882 (the "'882 application"), filed March 4, 2002, which is a continuation of U.S. Patent Application Serial No. 09/471,958, filed December 23, 1999 (the "'958 application"), now US 6,365,184, issued April 2, 2002, which is a continuation of U.S. Patent Application Serial No. 08/793,078, filed February 13, 1997 (the "'078 application"), abandoned, which was the National Stage of International Application No. PCT/SE96/01735, filed December 20, 1996.

The documents identified on the attached form PTO-1449 include the patents, publications and other information which were previously cited by or submitted to the Office in the great-grandparent '078 application, the grandparent '958 application, and the parent '882 application. Pursuant to C.F.R. §1.98(d), copies of the identified documents are not required in connection with this Information Disclosure Statement as copies were submitted or cited in the preceding '078, '958, and '882 applications and the present continuation application relies upon the earlier filing dates of the '078, '958, and '882 applications under 35 U.S.C. §120.

#### TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with a continuation application.

Applicants submit that no fee is required in connection with this submission. However, if any fee is due in connection with the communication, authorization is hereby given to charge Account No. 23-1703.

Dated: July 14, 2003

Respectfully submitted,

John M. Genova Reg. No. 32,224

Attorney for Applicants

Attorney Direct Dial: (212) 819-8832

Client No. 007470 (212) 819-8200

FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 1103326-0250	Serial No. TBA
INFORM	ATION DISCLOSURE STATEMENT	Applicant: Depui, et al.	
	BY APPLICANT	Filing Date: TBA	Group: 1615

*Examiner Initial	Document No.				Date	Name	C1ass	Sub- Class	Filing Date, if Appropriate			
	4	7	8	6	5	0	5	11-88	Lovgren et al.	424	468	
	5	4	1	7	9	8	0	05/23/95	Goldman et al.	424	464	

### FOREIGN PATENT DOCUMENTS

	Document No.							Date	Country	Class	Sub- Class	Trans Yes	lation No
	0	0	7	2	0	2	1	08/82	EP				
	8	5	0	1	2	0	7	09/84	wo				
	0	5	8	7	2	2	0	08/93	EP				
	0	5	4	1	3	6	9	11/92	EP				
	2	2	8	5	9	8	9	01/95	GB				
	9	4	0	3	1	6	0	07/93	wo				
	0	6	4	8	4	8	7	10/94	ЕР				
	0	1	0	8	5	0	4	10/83	EP				
	8	5	0	3	4	3	6	02/85	wo				
	2	0	6	6	0	7	0	12/80	GB				
	2	1	3	2	8	8	7	11/83	GB				

# OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

7 Millimidian delois de l'olisie		D.M. 1989 Gastroenterology 96:662-674, "Nonsteroidal matory Drug-Induced Ulcers"	
----------------------------------	--	--	--

Examiner:

Date Considered:

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 1103326-0250	Serial No. TBA
INFORM	MATION DISCLOSURE STATEMENT	Applicant: <b>Depui, et al.</b>	
	BY APPLICANT	Filing Date: TBA	Group: 1615

*Examiner Initial	Do	cum	nent	t No.				Date	Name		Sub- Class	Filing Date, if Appropriate
	5	7	5	3	2	6	5	05/19/88	Bergstrand et al	424	474	

### FOREIGN PATENT DOCUMENTS

	Do	cun	nent	No				Date	Country	Class	Sub- Class	Trans Yes	lation No
	0	1	1	1	1	0	3	10/83	EP				
	0	0	8	0	3	4	1	11/82	EP				
	2	0	9	1	0	9	7	11/81	GB				
	0	1	7	0	7	5	2	12/84	EP				
	0	0	1	3	5	6	6	01/90	EP		,		
	0	1	0	8	2	9	5	10/83	EP				
	8	7	0	2	2	4	0	09/86	wo				
	9	3	1	2	7	7	2	12/92	wo				
	0	3	9	1	5	1	8	02/90	EP				
	0	0	0	8	7	8	0	08/79	EP				
	9	5	1	0	2	6	4	4/20/95	wo				X

# OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

Walan, A. Et al. 1989 "Effect of omeprazole and ranitine on ulcer healing" The N.E. J. Med 320:69.	
--	--

Examiner:

Date Considered:

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 1103326-0250	Serial No. TBA
INFORM	ATION DISCLOSURE STATEMENT	Applicant: <b>Depui, et al.</b>	
	BY APPLICANT	Filing Date:	Group:
		1211	1615

*Examiner Initial	Document No.						Date	Name		Filing Date, if Appropriate

### FOREIGN PATENT DOCUMENTS

	Do	cur	nent	t No	),			Date	Country	Class	Sub- Class	Translar Yes	tion No
	9	7	2	5	0	6	4	7-97	WIPO				
	0	4	2	6	4	7	9	5-90	EP				
	0	2	4	7	9	8	3	12-87	EP				
	0	3	6	5	9	4	7	5-90	EP				

# OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

Guess, H.A. et al. 1988 "Fatal upper gastrointestinal hemorrhage or perforation" J. Clin. Epidimol 41:35-45
Larkai, E.N. et al. 1987 "Gastroduodenal mucosa and dyspeptic symptoms" Am. J. Gastroenterology 82:1153
Catford, J.C. et al. 1986 "Confidential inquiry into deaths from peptic ulcer" Health Trends 18:37-41
Hawkey C. "Non-steroidal anti-inflammatory drugs and peptic ulcers" (1990) 300:278-284
Scheiman, J.M. "Pathogenesis of gastroduodenal injury" (1982) Semin. Arthritis Reheum. 21(4):201-210-
 Walan, A. Et al. 1989 "Effect of omeprazole and ranitine on ulcer healing" The N.E. J. Med 320:69.

Examiner: Date Considered:

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No 1103326-0250	Serial No. <b>TBA</b>
INFORM	MATION DISCLOSURE STATEMENT	Applicant: <b>Depui, et al.</b>	
	BY APPLICANT	Filing Date: TBA	Group: 1615

*Examiner Initial	Document No.							Date Name				Filing Date, if Appropriate	
	5 8 1 7 3 3 8		06.10.98	Bergstrand et al.	424	474							
	5	7	6	3	4	2	2	09.07.98	Lichtenberger et al	514	78	12.05.95	
	5	9	5	5	4	5	1	21.09.99	Lichtenberger et al	514	78	24.09.96	

## FOREIGN PATENT DOCUMENTS

	Do	cun	nent	: No	•			Date	Country	Class	Sub- Class	Translation Yes   No		
	9	8	2	2	1	1	7	28.05.98	wo					
	9	8	2	2	1	1	8	28.05.98	wo					

# OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

 Drug Facts and Comparisons 1994, pages 1679-1684
Remington: The Science and Practice of Pharmacy, chapter 93, 1650-1656, 1995
Wan, L.S.C., "A Multiple-unit Tablet Formulation for Multi-layer Drug-coated Granules", S.T.P. PHARMA SCIENCES, 4(5)(1994), PP-336-342.

Examiner: Date Considered:

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	cume	BY	API O.	PLICED 8	CAN	NT	S PAT	TENT DOCUM Name DePui, et al.	Dep Filir TBA		e:	Sub- Clas	- F	ilin	up: 615 ng Da	
6	3 (	U ent N	JNIT o.	FED 8	STA	ATES	e	Name	TBA	S			- F	ilin	.615 ng Da	
6	3 (	ent N	0.	8		Date	e	Name	IENT		SS					
6	3 (	-	1		4					Clas	S					
		6 5			4	4/20	002	DePui, et al.								
nent	No.		F	ORF												
nent i	No.		F	ORE												
nent i	No.			OICL	EIGI	N PA	TEN	T DOCUMENT	ΓS							
							Dat	e	Country		C			o- SS	Tran: Yes	slation   No
0	2	2	2	1	0	8	21 1	Mar. 2002	wc	)			•			
9	5	0	9	8	3	1	13 /	Apr. 1995	WC	)						
9	5	3	0	6	4	1	161	Nov. 1995	WC	0						
9	4	1	2	4	6	3	9 Ju	ine 1994	WC	wo						
0	1	6	6	0	8	7	13 9	Sept. 2001	WC	vo						
9	4	0	4	4	8	4	3 M	Iar. 1994	WC	)						
8 - 3 0 1 7 6					3 19 Nov. 1996			JP						X		
			<u> </u>	·			<u> </u>									L
									e, Per	inent	Pa	ges, E	etc.)			
hem.	Phar	m. B	ull.,	42(1	1),	2327	-2331	(1994)								
hem.	Phar	m. B	ull.,	44(7	<u>'), 1</u>	361-1	1366	(1996)		•		-				
						Date	Cons	idered:								
	9 9 9 7 FHEI	9 5 9 4 0 1 9 4 - 3  THER DC hem. Phar hem. Phar	9 5 0 9 5 3 9 4 1 0 1 6 9 4 0 - 3 0  THER DOCUM hem. Pharm. B hem. Pharm. B	9 5 0 9 9 5 3 0 9 4 1 2 0 1 6 6 9 4 0 4 - 3 0 1  THER DOCUMEN hem. Pharm. Bull., hem. Pharm. Bull.,	9 5 0 9 8 9 5 3 0 6 9 4 1 2 4 0 1 6 6 0 9 4 0 4 4 - 3 0 1 7  THER DOCUMENTS ( hem. Pharm. Bull., 42(1) hem. Pharm. Bull., 44(7)	9 5 0 9 8 3 9 5 3 0 6 4 9 4 1 2 4 6 0 1 6 6 0 8 9 4 0 4 4 8 - 3 0 1 7 6  THER DOCUMENTS (included)  Them. Pharm. Bull., 42(11), them. Pharm. Bull., 44(7), 1  Initial citation considered, rough citation if not in considered.	9 5 0 9 8 3 1 9 5 3 0 6 4 1 9 4 1 2 4 6 3 0 1 6 6 0 8 7 9 4 0 4 4 8 4 - 3 0 1 7 6 3  THER DOCUMENTS (including them. Pharm. Bull., 42(11), 2327 hem. Pharm. Bull., 44(7), 1361-1  Date  Initial citation considered, whether rough citation if not in conformatical citation citation in conformatical citation in conformatical citation in conformatical citation in conformatical citation citation in conformatical citation citation in conformatical citation	9 5 0 9 8 3 1 13 2 9 5 3 0 6 4 1 161 9 4 1 2 4 6 3 9 July 10 1 6 6 0 8 7 13 5 9 4 0 4 4 8 4 3 Muly 10 1 7 6 3 19 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	9 5 0 9 8 3 1 13 Apr. 1995 9 5 3 0 6 4 1 16 Nov. 1995 9 4 1 2 4 6 3 9 June 1994 0 1 6 6 0 8 7 13 Sept. 2001 9 4 0 4 4 8 4 3 Mar. 1994 - 3 0 1 7 6 3 19 Nov. 1996  THER DOCUMENTS (including Author, Title, Date them. Pharm. Bull., 42(11), 2327-2331 (1994) hem. Pharm. Bull., 44(7), 1361-1366 (1996)  Date Considered:  Initial citation considered, whether or not citation is rough citation if not in conformance and not considered.	9 5 0 9 8 3 1 13 Apr. 1995 WC 9 5 3 0 6 4 1 16 Nov. 1995 WC 9 4 1 2 4 6 3 9 June 1994 WC 0 1 6 6 0 8 7 13 Sept. 2001 WC 9 4 0 4 4 8 4 3 Mar. 1994 WC - 3 0 1 7 6 3 19 Nov. 1996 JP  THER DOCUMENTS (including Author, Title, Date, Perthem. Pharm. Bull., 42(11), 2327-2331 (1994)  hem. Pharm. Bull., 44(7), 1361-1366 (1996)  Date Considered:  Initial citation considered, whether or not citation is in corough citation if not in conformance and not considered.	9 5 0 9 8 3 1 13 Apr. 1995 WO 9 5 3 0 6 4 1 16 Nov. 1995 WO 0 1 6 6 0 8 7 13 Sept. 2001 WO 9 4 0 4 4 8 4 3 Mar. 1994 WO - 3 0 1 7 6 3 19 Nov. 1996 JP  THER DOCUMENTS (including Author, Title, Date, Pertinent them. Pharm. Bull., 42(11), 2327-2331 (1994)  them. Pharm. Bull., 44(7), 1361-1366 (1996)  Date Considered:  Initial citation considered, whether or not citation is in conform rough citation if not in conformance and not considered. Include	9 5 0 9 8 3 1 13 Apr. 1995 WO 9 5 3 0 6 4 1 16 Nov. 1995 WO 9 4 1 2 4 6 3 9 June 1994 WO 0 1 6 6 0 8 7 13 Sept. 2001 WO 9 4 0 4 4 8 4 3 Mar. 1994 WO - 3 0 1 7 6 3 19 Nov. 1996 JP  THER DOCUMENTS (including Author, Title, Date, Pertinent Pathem. Pharm. Bull., 42(11), 2327-2331 (1994) hem. Pharm. Bull., 44(7), 1361-1366 (1996)  Date Considered:  Initial citation considered, whether or not citation is in conformant rough citation if not in conformance and not considered. Include of	9 5 0 9 8 3 1 13 Apr. 1995 WO 9 5 3 0 6 4 1 16 Nov. 1995 WO 0 1 6 6 0 8 7 13 Sept. 2001 WO 9 4 0 4 4 8 4 3 Mar. 1994 WO - 3 0 1 7 6 3 19 Nov. 1996 JP  THER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Edm. Pharm. Bull., 42(11), 2327-2331 (1994)  hem. Pharm. Bull., 44(7), 1361-1366 (1996)  Date Considered:  Initial citation considered, whether or not citation is in conformance with rough citation if not in conformance and not considered. Include copy of	9 5 0 9 8 3 1 13 Apr. 1995 WO 9 5 3 0 6 4 1 16 Nov. 1995 WO 9 4 1 2 4 6 3 9 June 1994 WO 0 1 6 6 0 8 7 13 Sept. 2001 WO 9 4 0 4 4 8 4 3 Mar. 1994 WO - 3 0 1 7 6 3 19 Nov. 1996 JP  THER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) hem. Pharm. Bull., 42(11), 2327-2331 (1994) hem. Pharm. Bull., 44(7), 1361-1366 (1996)  Date Considered:  Initial citation considered, whether or not citation is in conformance with M rough citation if not in conformance and not considered. Include copy of this	9 5 0 9 8 3 1 13 Apr. 1995 WO 9 5 3 0 6 4 1 16 Nov. 1995 WO 9 4 1 2 4 6 3 9 June 1994 WO 0 1 6 6 0 8 7 13 Sept. 2001 WO 9 4 0 4 4 8 4 3 Mar. 1994 WO - 3 0 1 7 6 3 19 Nov. 1996 JP  THER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) hem. Pharm. Bull., 42(11), 2327-2331 (1994) hem. Pharm. Bull., 44(7), 1361-1366 (1996)  Date Considered:  Initial citation considered, whether or not citation is in conformance with MPE rough citation if not in conformance and not considered. Include copy of this for	9 5 0 9 8 3 1 13 Apr. 1995 WO 9 5 3 0 6 4 1 16 Nov. 1995 WO 9 4 1 2 4 6 3 9 June 1994 WO 0 1 6 6 0 8 7 13 Sept. 2001 WO 9 4 0 4 4 8 4 3 Mar. 1994 WO - 3 0 1 7 6 3 19 Nov. 1996 JP X  THER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) hem. Pharm. Bull., 42(11), 2327-2331 (1994) hem. Pharm. Bull., 44(7), 1361-1366 (1996)  Date Considered:  Initial citation considered, whether or not citation is in conformance with MPEP 609 rough citation if not in conformance and not considered. Include copy of this form w